EHA 2022 | LAVA-051: a novel bispecific T-ce... - CLL Support

CLL Support

22,616 members38,843 posts

EHA 2022 | LAVA-051: a novel bispecific T-cell engager for R/R hematological malignancies

Jm954 profile image
Jm954Administrator
0 Replies

Another novel bispecific T-cell engager for the R/R group of patients bringing hope to patients who have exhausted treatment options. This one targets a very small group of T cells and hopefully the side effects (tumour lysis, possible ICANS) will be minimised.

Short video of almost 2 minutes

vjhemonc.com/video/o_fdwkhb...

Jackie

Written by
Jm954 profile image
Jm954
Administrator
To view profiles and participate in discussions please or .

You may also like...

More CAR-T: Looking Back to Go Forward in CAR-T Cell Therapy in R/R CLL

(6 of 12 patients). The response rate increased to 80% (4 of 5 patients) when only patients who...

Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell CLL

total and virus-specific CD8+ T cells in 65 patients with CLL and 14 patients undergoing long-term...

Starting therapy 5 yrs post CAR-T with another immunotherapy trial, now epcoritamab

of epcoritimab, a novel bispecific monoclonal T-cell engine antibody, and hopefully heading home...

More on Cytokine Release Syndrome toxicities associated with CAR-T-cell therapy.

support. The likelihood of a patient experiencing severe CRS depends on patient-, tumor-, and...

Update on my status 3 month post chemo (FCR)- doing well - no malignant B cells in my MRD test

all normal, neutrophils are going up, red blood cells and platelets going up since last visit 3...